A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer
Metrics: PDF 772 views | HTML 1090 views | ?
Ke-Jun Liu1,2, Hai-Ying Wu1
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
2Department of Medical Oncology, Dongguan People’s Hospital, Dongguan, China
Hai-Ying Wu, e-mail: email@example.com
Keywords: non-small-cell lung cancer (NSCLC), bevacizumab, platinum-based chemotherapy
Received: April 29, 2015 Accepted: May 30, 2015 Published: June 11, 2015
Patients with non-small-cell lung cancer (NSCLC) often have an advanced disease when firstly diagnosed. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR). In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. Results showed that the objective response rate(ORR) of this novel regimen is 43%, median progression-free survival (PFS) was 5.2 months (95% CI, 3.7 to 6.7 months) and median overall survival (OS) was 11.4 months (95% CI, 8.8 to 13.9 months). Adverse events were generally mild, ranging from grade 1 to grade 3. In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. Randomized clinical trials are needed to further investigate the efficacy of this regimen.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.